Crispr Stock, A Cathie Wood’s Holding, Dives For The Fifth Straight Week — Here’s Why
Crispr stock is tumbling for the fifth straight week as the top Cathie Wood’s holding struggles amid dimming expectations for its new Vertex-partnered gene-editing drug. X Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) gained Food and Drug Administration approval for Casgevy on Dec. 8. On the same day, the FDA signed off on a rival … Read more